Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
97pct
489d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Tibet Independence Act This bill addresses and imposes sanctions relating to Tibet. The bill states that it is U.S. policy to affirm that China's territorial claims over Tibet are invalid and without merit. It also authorizes the President to recognize Tibet as a separate and independent country. The President must impose property- and visa-blocking sanctions on foreign persons that are knowingly responsible for or complicit in supporting the Chinese Communist Party's occupation of Tibet.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; Issues to related to Biotechnology and Biosecurity best practices; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; H.R. 791/S. 236, Tracking COVID-19 Variants Act; S.3534/H.R.7152, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act H. Rpt. 107-443, Explanatory Statement accompanying Division H - Departments of Labor, Health and Human Services, and Education, and related Agencies Appropriations Act, 2023 - related to whole genome sequencing
Referred to the Subcommittee on Immigration and Citizenship.
Referred to the Committee on Foreign Affairs, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Issues related to genomics, sequencing, and surveillance; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Chips and Science Act (PL 117-167); H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; S. 3799, PREVENT Pandemics Act; S. 3534, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Health Issues
Discussions related to genomics, sequencing and the applications for sequencing including in rare disease and related reimbursement; S. 2022, Ending the Diagnostic Odyssey Act; H.R. 6000, Cures 2.0 Act; Ongoing monitoring of CDC surveillance funding; Chips and Science Act (PL 117-167); H.R. 791/S. 236, Tracking COVID-19 Variants Act; H.R. 5376, Inflation Reduction Act of 2022; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; S. 3819, Advanced Research Project Authority for Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; H.R. 7007, COVID Supplemental Appropriations Act, 2022; S. 3799, PREVENT Pandemics Act; Issues related to the FY 2023 President's Budget; S.3534/H.R.7152, Tracking Pathogens Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including H.R. 4281/S. 2209, VALID Act
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE